Sugi Predict

Sugi Predict / Compounds / SCHEMBL988141

SCHEMBL988141

SCHEMBL988141

O=C(O)c1ccc(CNC(=O)c2cccc3ccn(Cc4cc5ccccc5o4)c23)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 1/20 0.48
▸ KMT2A Q03164 2/20 0.47
▸ KDM4E B2RXH2 2/20 0.47
▸ PTGER4 P35408 4/20 0.47
▸ PTGDR Q13258 4/20 0.47
▸ ALDH1A1 P00352 3/20 0.47
▸ TP53 P04637 2/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ HPGD P15428 1/20 0.47
▸ NR1H4 Q96RI1 3/20 0.46
▸ TBXA2R P21731 1/20 0.45
▸ PTGER1 P34995 1/20 0.45
▸ PTGFR P43088 1/20 0.45
▸ PTGER3 P43115 1/20 0.45
▸ PTGER2 P43116 1/20 0.45
▸ TDP1 Q9NUW8 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ MAPT P10636 2/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ GLA P06280 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12584612 0.90 KDM4E (0.61) MAOBKMT2AKDM4EALDH1A1TP53
SCHEMBL12585726 0.83 PTGER4 (0.67) PTGER4PTGDRALDH1A1POLB
SCHEMBL12584456 0.82 STING1 (0.48) MAOBKMT2APTGER4PTGDRMEN1
SCHEMBL29518204 0.82 STING1 (0.48) MAOBKMT2APTGER4PTGDRMEN1
SCHEMBL12585567 0.82 NR1H4 (0.57) PTGER4PTGDRNR1H4TBXA2RPTGER1
SCHEMBL12585751 0.81 PTGER4 (0.47) PTGER4PTGDRALDH1A1NR1H4TBXA2R
SCHEMBL10085256 0.81 PTGER4 (0.59) PTGER4PTGDRALDH1A1HPGDNR1H4
SCHEMBL12585654 0.79 NR1H4 (0.48) PTGER4PTGDRALDH1A1NR1H4TBXA2R
SCHEMBL23890339 0.79 DRD2 (0.38) MAOBKMT2APTGER4PTGDRTBXA2R
SCHEMBL28484362 0.79 NPC1 (0.38) MAOBPTGER4PTGDRTBXA2RPTGER1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8598355-B2 Amide compound ASTELLAS PHARMA INC. (JP) 2013-12-03 — — US disclosed
EP-2565191-A1 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy Astellas Pharma Inc. (JP) 2013-03-06 — — EP disclosed
US-20110144153-A1 AMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-06-16 — — US disclosed
US-20110144153-A1 AMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-06-16 — — US disclosed
US-20110144153-A1 AMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-06-16 — — US disclosed
EP-2277858-A1 AMIDE COMPOUND Astellas Pharma Inc. (JP) 2011-01-26 — — EP disclosed
EP-2277858-A1 AMIDE COMPOUND Astellas Pharma Inc. (JP) 2011-01-26 — — EP disclosed
WO-2009139373-A1 AMIDE COMPOUND アステラス製薬株式会社 (JP) 2009-11-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144153-A1 AMIDE COMPOUND PTGER4, PTGER1, PTGER2 MAOB 4294/4885KMT2A 2272/4885KDM4E 959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.